GBT
UTHR icon

Grove Bank & Trust’s United Therapeutics UTHR Stock Holding History

Grove Bank & Trust’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-329
Closed -$43K – 663
2017
Q2 		$43K Buy
329
+54
+20% +$6.74K 0.03% 271
2017
Q1 		$37K Hold
275
– – 0.03% 244
2016
Q4 		$39K Buy
+275
New +$35.1K 0.03% 256

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Grove Bank & Trust's UTHR Position: Q3 2017 in Review

Grove Bank & Trust sold out of United Therapeutics (UTHR) in Q3 2017, closing a stake of 329 shares — an estimated $43K sold.

Grove Bank & Trust first reported a position in UTHR in Q4 2016 and held it in 3 quarters. The position peaked at $43K in Q2 2017. 373 funds tracked by Wall St. Rank hold UTHR as of Q3 2017.

  • Grove Bank & Trust reported no remaining United Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Grove Bank & Trust sold 329 United Therapeutics shares in Q3 2017, an estimated $43K.
  • Grove Bank & Trust first reported a position in United Therapeutics in Q4 2016 and held it in 3 quarters.
  • Grove Bank & Trust's United Therapeutics position peaked at $43K in Q2 2017.
  • 373 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2017.

Based on Grove Bank & Trust's 13F filing for Q3 2017, filed 13 Nov 2017.